Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines. Repatha belongs to a potent new class of drugs known as PCSK9 inhibitors that are extremely effective at lowering “bad” LDL cholesterol. NICE, which decides if treatments should be paid for on the National Health Service (NHS), also said in its draft guidance that analyses presented by Amgen had limitations that “called into question the reliability of the cost-effectiveness results”.
The rest is here:
UK cost watchdog turns down Amgen’s new cholesterol drug